By MATTHEW PERRONE
WASHINGTON (AP) — The Food and Drug Administration’s embattled vaccine chief, Dr. Vinay Prasad, is once again leaving the agency — the second time in less than a year that he’s departed after controversial decisions involving the review of vaccinations and specialty drugs for rare diseases.
Related Articles
Justice Department official eyes cases against Cuba leaders as Trump floats ‘friendly takeover’
A $220 million ad blitz and a public split with Trump mark the end of Kristi Noem’s DHS tenure
‘Come and take it’: Massachusetts governor challenges RFK Jr.’s request for Dunkin’, Starbucks ingredients
Kennedy Center exodus continues as National Symphony director Jean Davidson heads to the Wallis
Judge weighs bid to block policy limiting journalists’ access to Pentagon
FDA Commissioner Marty Makary announced the news to FDA staff in an email late Friday, saying Prasad would depart at the end of April. Makary said Prasad would return to his academic job at the University of California, San Francisco.
Prasad’s latest ouster follows a string of high-profile controversies involving the FDA’s review of vaccines, gene therapies and biotech drugs in which companies have criticized the agency for reversing itself, in some cases calling for new trials of products previously greenlighted by regulators.
In July, Prasad was briefly forced from his job after running afoul of biotech executives, patient groups and conservative allies of President Donald Trump. He was reinstated less than two weeks later with the backing of Health Secretary Robert F. Kennedy Jr. and Makary.
FILE – In this undated photo provided by the U.S. Food and Drug Administration, Vinay Prasad smiles for a portrait. (U.S. FDA via AP)
A longtime academic and critic of the FDA’s standards for drug reviews, Prasad has taken a seemingly contradictory approach to regulation since arriving at the FDA last May. On repeated occasions, Prasad has joined Makary in announcing steps to make FDA drug reviews faster and easier for companies. But he also has imposed new warnings and study requirements for some biotech drugs and vaccines, particularly COVID shots that have long been a target for Kennedy, a longtime anti-vaccine activist before joining the Trump administration.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Leave a Reply